Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Merck Patent GmbH | 3,916 |
| 2 | BASF SE | 2,635 |
| 3 | Takeda Pharmaceutical Co Ltd | 2,038 |
| 4 | Merck Sharp & Dohme LLC | 1,967 |
| 5 | Bristol Myers Squibb Co | 1,616 |
| 6 | Bayer CropScience AG | 1,018 |
| 7 | Fujifilm Holdings Corp | 785 |
| 8 | Incyte Corp | 748 |
| 9 | Astellas Pharma Inc | 737 |
| 10 | AstraZeneca AB | 729 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | C07D | Heterocyclic compounds | 34,979 |
| 2 | A61P | Therapeutic activity (drug indications) | 27,631 |
| 3 | A61K | Medicinal preparations | 18,145 |
| 4 | C07C | Acyclic and carbocyclic compounds | 6,371 |
| 5 | A01N | Preservation of bodies; biocides; pest repellents | 5,723 |
| 6 | C09K | Materials for misc. applications | 5,568 |
| 7 | H10K | Organic semiconductors / OLEDs | 4,827 |
| 8 | C07F | Organometallic compounds | 4,710 |
| 9 | Y02E | Climate change mitigation: energy | 4,185 |
| 10 | Y02P | Climate change mitigation: production | 1,800 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Polymer of 1,2,4-thiadiazole and lubricants containing it as an additive | 1978 | Arkema Inc | 69 |
| Novel disulfides derived from 1,2,4-thiadiazole | 1975 | Lubrizol Corp | 54 |
| 1,2,4-THIADIAZOLE DERIVATIVES ANTIFUNGAL COMPOUNDS, COMPOSITIONS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | 2007 | BARBEY, SABINE | 44 |
| 3,5-Di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxiphenyl- 1,2,4-thiadiazoles, -oxadiazoles as antiinflammatory agents | 1990 | Warner Lambert Co LLC | 33 |
| 1,2,4-oxadiazole and 1,2,4-thiadiazole derivatives of fenamates as antiinflammatory agents | 1992 | Warner Lambert Co LLC | 31 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Peroxisome Proliferator-Activated Receptors | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Aihua Wang | Johnson & Johnson (United States) | 2 |
| 2 | Alan C. Gibbs | Johnson & Johnson (United States) | 2 |
| 3 | Ana Castro | Instituto de Química Médica | 2 |
| 4 | Arantxa Encinas | Instituto de Química Médica | 2 |
| 5 | Carmen Gil | Instituto de Química Médica | 2 |
| 6 | Ellen Sieber-McMaster | Johnson & Johnson (United States) | 2 |
| 7 | Gee‐Hong Kuo | Johnson & Johnson (United States) | 2 |
| 8 | HU Zhi-yong | Johnson & Johnson (United States) | 2 |
| 9 | Hamish Ross | Johnson & Johnson (United States) | 2 |
| 10 | Jolanta Wodzinska | Apotex (Canada) | 2 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Advances in the synthesis and recent therapeutic applications of 1,2,4-thiadiazole heterocycles | 2005 | 155 | Synthesis and biological activity |
| Cu(II)- and Hg(II)-Induced Modulation of the Fluorescence Behavior of a Redox-Active Sensor Molecule | 2001 | 123 | Electrochemical sensors and biosensors |
| 1,2,4-Thiadiazole: A novel Cathepsin B inhibitor | 2003 | 81 | Protease and Inhibitor Mechanisms |
| Synthesis and evaluation of novel dipeptide-bound 1,2,4-Thiadiazoles as irreversible inhibitors of guinea pig liver transglutaminase | 2001 | 57 | Blood properties and coagulation |
| A Rational Chemical Intervention Strategy To Circumvent Bioactivation Liabilities Associated with a Nonpeptidyl Thrombopoietin Receptor Agonist Containing a 2-Amino-4-arylthiazole Motif | 2007 | 52 | Platelet Disorders and Treatments |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of 1,2,4-thiadiazole?
Which organizations hold the most patents related to 1,2,4-thiadiazole?
What are the primary research areas for 1,2,4-thiadiazole based on patent classification?
What biological applications of 1,2,4-thiadiazole have been documented in literature?
How has patent activity for 1,2,4-thiadiazole evolved recently?